Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort

Metabolism: Clinical and Experimental

Volumn 60, Issue 10, 2011, Pages 1363-1371

  Baur, Dorothee M ^a,b,c   Klotsche, Jens ^d   Hamnvik, Ole Petter R ^e   Sievers, Caroline ^f   Pieper, Lars ^d   Wittchen, Hans Ulrich ^d   Stalla, Günter K ^f   Schmid, Roland M ^c   Kales, Stefanos N ^a,b   Mantzoros, Christos S ^g,h  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; MEGLITINIDE; METFORMIN;

ADULT; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; FEMALE; GERMANY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; PREVALENCE; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 80052968453     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.09.012     Document Type: Article

References (21)

1. Coughlin S.S. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults Am J Epidemiol 159 2004 1160 1167 (Pubitemid 38747263)
2. Larsson S.C., Mantzoros C.S., and Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 121 2007 856 862 (Pubitemid 47106217)
3. Vigneri P. Diabetes and cancer Endocr Relat Cancer 16 2009 1103 1123
4. Wild S. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
5. Giovannucci E., and Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas Gastroenterology 132 2007 2208 2225 (Pubitemid 46693749)
6. Bowker S.L. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 2006 254 258 (Pubitemid 44106500)
7. Currie C.J., Poole C.D., and Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 2009 1766 1777
8. Monami M. Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study Exp Clin Endocrinol Diabetes 116 2008 184 189 (Pubitemid 351518539)
9. Yang Y.X., Hennessy S., and Lewis J.D. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients Gastroenterology 127 2004 1044 1050 (Pubitemid 39345873)
10. Evans J.M. Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305 (Pubitemid 40813563)
11. Landman G.W. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 Diabetes Care 33 2010 322 326
12. Libby G. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
13. Monami M. Sulphonylureas and cancer: a case-control study Acta Diabetol 46 2009 279 284
14. Gerstein H.C. Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 303 2010 446 447
15. Schneider H.J. Prevalence of low male testosterone levels in primary care in Germany: cross-sectional results from the DETECT study Clin Endocrinol (Oxf) 70 2009 446 454
16. Sievers C., Schneider H.J., and Stalla G.K. Insulin-like growth factor-1 in plasma and brain: regulation in health and disease Front Biosci 13 2008 85 99 (Pubitemid 351606125)
17. Wittchen H.U. Cardiovascular risk factors in primary care: methods and baseline prevalence rates-the DETECT program Curr Med Res Opin 21 2005 619 630
18. Nath N. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis J Immunol 182 2009 8005 8014
19. Oba S. Self-reported diabetes mellitus and risk of mortality from all causes, cardiovascular disease, and cancer in Takayama: a population-based prospective cohort study in Japan J Epidemiol 18 2008 197 203
20. Ogunleye A.A. A cohort study of the risk of cancer associated with type 2 diabetes Br J Cancer 101 2009 1199 1201
21. Campbell R.K. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies J Am Pharm Assoc (2003) 49 Suppl 1 2009 S3 S9